A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

• Status: Active, not recruiting
• Trial end date: 2022-07-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie
• Collaborator: Genentech, Inc.
• Treatments: Azacitidine; Venetoclax

Criteria

Inclusion Criteria:

• Participant must have documented diagnosis of untreated de novo MDS with:

• International Prognostic Scoring System (IPSS) risk categories Int-2 or High (minimum IPSS overall score of 1.5) OR Revised IPSS (IPSS-R) categories intermediate, high or very high (score of > 3) and

• Presence of less than 20% bone marrow blasts per bone marrow biopsy/aspirate.

• Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.

Exclusion Criteria:

• Participant has received prior therapy for MDS. (Prior supportive care in form of transfusions or growth factors, etc., is not considered prior therapy).

• Participant has received prior therapy with a BCL-2 Homology 3 (BH3) mimetic.

• Participant has a diagnosis other than previously untreated de novo MDS (as defined in the protocol) including:

• MDS with IPSS risk categories Low or Int-1 (overall IPSS score < 1.5)

• Therapy-related MDS (t-MDS).

• MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).

• MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.

• Participant has received allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or solid organ transplantation.

• Participant has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.